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Clinical evidence in IFNλ4
polymorphisms associated with HCV
infection in patients with beta
thalassemia 
and 
WGCNA  analysis weighted for IFNλ4
genotype (rs12979860) to detect
RPL9P18 as hub in HCV infected cell.

Abstract
Genome-wide association studies have identified host genetic variation to be critical 
for spontaneous clearance and treatment response in patients infected with hepatitis C
virus (HCV). We demonstrated the same in patients with thalassemia major infected 
by genotype 1b of HCV.
In the present first part study we retrospectively analyzed 368 anti-HCV positive 
patients with beta-thalassemia in two Italian major  thalassemic centers (Cagliari and 
Turin). 
The strongest IFNλ4 SNP found associated with HCV was rs12979860 where C/C 
genotype was related to response to the interferon treatment and, above all, to 
spontaneous clearance of the virus. However, the positive predictive power was 
stronger for viral persistence than spontaneous clearance indeed TT allele was more 
predictive than CC. 
Another polymorphism rs4803221 was analyzed because had independent effects 
respect to rs12979860. The haplotype tagged by SNP rs12979860 and rs4803221 
significantly could improve the viral clearance prediction in infected patients. 
Neither necrotic-inflammation or bilirubin values in the chronic phase of the hepatitis
C were related to IFNλ4 polymorphisms. No relation among IFNλ4 polymorphisms 
and fibrosis stage directly shown by the liver biopsy was found.
Second part of our study was to identify hub genes associated in pathways closely 
related to IFNλ4 variants in HCV response. We used gene expression profile data of 
GSE54648, downloaded from Gene Expression Omnibus (GEO). We focused our 
attention on expression genes differential between rs12979860 unfavorable TT 
genotype and favorable CC genotype, using weighted gene expression network 
analysis (WGCNA - R package). Significant modules were selected using the 
clustering analysis. At the final the best significant module was “black” module. Its 
pathways were involved in translation mechanisms such as translation termination, 
translation elongation, nuclear-transcribed mRNA catabolic process, cellular protein 
complex disassembly, therefore biological mechanisms that occur inside ribosome.
We discovered RPL9P18 pseudogene as a hub potentially related in inhibition of 
spontaneous clearance and furthermore likely involved in drug treatment inhibition. 
Our result suggests an active role for ribosome pseudogene in innate antiviral 
response probably during ISG (IFN-stimulated genes) translation. Moreover, through 
co-expression analysis we demonstrate a new possible role of IFNλ4 genotype in 
HCV infection, associate with expression of ribosomal  pathways.
Introduction
Background
Some 3% of the World's population is infected with the hepatitis C virus (HCV). In 
most cases, the virus, if either untreated or treated but not cleared, causes chronic 
infection and thereby increases the risk of liver fibrosis and liver cancer. HCV 
infection is also the major cause of liver transplantation. The current standard of care 
is pegylated-interferon and ribavirin, which clears the virus only after weekly 
injections for up 48 weeks and in less than half of those infected with the most 
common form of the virus, genotype 1.
Hepatitis C, as with all viruses, seeks entry into human host cells to evade the 
dangerous extracellular milieu repleted with cytokines, natural killer cells, 
macrophages and interferon each seeking to destroy the virus. Once inside the 
hospitable hepatocyte, the HCV uses its RNA as a template for replication. Into the 
trillions of new copies every day.
The majority of people infected with hepatitis C virus (HCV) develops chronic 
infection, which can remain asymptomatic for many years, ultimately leading to the 
development of liver fibrosis, cirrhosis, and hepatocellular carcinoma (Brown et al., 
2005; Alter and Liang et al., 2012). Interestingly, 20%-30% of people infected with 
HCV are able to clear the infection and do not progress to chronicity. The molecular 
mechanisms driving this clinical dichotomy remain unknown, in part for the 
complications to study HCV in its native environment, the human hepatocyte in the 
liver.
In 2009, four independent groups, using genome wide association studies (GWAS), 
identified SNPs from IFNλ4 [RefSeq:NM_172139.2] region that could predict drug 
response. A further study demonstrated that viral clearance without therapy was also 
predicted by these SNPs. Previously, prediction of treatment failure was based on 
phenotypic features such as viral load, body mass index, ethnicity and liver fibrosis. 
IFNλ4 genotype, however, predicts treatment failure with greater sensitivity and 
specificity.
SNPs at the IFNλ4 locus (e.g. rs12979860) are strongly associate with HCV 
clearance and treatment response, but the underlying mechanisms responsible  remain
unclear (Ge et al., 2009; Naggie et al., 2012; Thomas et al., 2009; Urban et al., 2010).
More recently, polymorphisms at an IFN-lambda locus (IFNλ3, IFNλ4), were shown 
to have similar predictive value, thus galvanizing the importance of IFNλ in HCV 
infection (Prokunina-Olsson et al., 2013). However many SNPs for IFNλ3 and IFNλ4
appear in strong linkage disequilibrium (Prokunina-Olsson et al., 2013), therefore 
rs12979860 could predict same HCV response, find other SNPs not in linkage 
disequilibrium is a research challenge.
It is desirable to predict treatment response or spontaneous clearance response for 
many reasons. For those unlikely to respond, alternative therapies are in late phase 
clinical trials and have a greatly improved success rate due to the ability to target 
those that are unlikely to respond to the standard treatment. Patients with non-
response genotype could therefore delay treatment, or have preferential use of the 
more expensive new therapies, which are all designed to be used in combination with 
the current standard of care. The predictive value of SNPs is better calculated from 
routine clinical practice, rather than the clinical trial scenario, since there are the 
conditions in which most patients are treated and where there is usually much lower 
compliance with drug usage regimens. Consequently, in first part of this study we 
used a new cohort (Sardinian population), to compare response rates for just known 
SNPs and other not well known SNPs. Thus, variants could be included to tag 
additional haplotype, for a better predictive values than the common haplotype.
Second part of our study is aimed to understand poorly known functional 
mechanisms in which IFNλ4 is involved during spontaneous clearance. For this 
purpose we used co-expression analysis method (WGCNA) from GEO dataset.
Hepatitis C virus relevance in Sardinia
Hepatitis C virus (HCV) is a single-stranded RNA virus belonging to the Flaviviridae 
family characterized by a high degree of genetic heterogeneity (Lai et al., 2013). 
The major routes of transmission are injection drug use, blood transfusion, 
hemodialysis, organ transplantation and less frequently, sexual intercourse. 
Controversial results have been reported about the relation between post-transfusion 
transmission, aggressive histological activity, and development of cirrhosis. Before 
the implementation of blood donor screening in 1991, the risk of acquiring post-
transfusion hepatitis C in Italy was about 20 cases per 1000 blood units. Although 
hepatitis C is no longer a major threat in the Italian blood supply, HCV acquired 
through transfusional before 1990 remains one of the most important problems 
among patients with thalassemia, given the reported presence of HCV antibodies in 
80%-90% of multi-transfused Italian patients and a prevalence of clinically 
significant fibrosis in 45% of them.
In patients with thalassemia major, post transfusional iron overload and HCV 
infection seem to be independent risk factors for liver fibrosis progression and their 
concomitant presence results in a greater risk. 
Multiple episodes of acute hepatitis C due to reinfection or reactivation of primary 
infection have been described.
IFNλ4 gene description
IFN-lambda is a cytokine that comes in two isoforms, IFNλ3 and IFNλ4, and plays a 
role in immune defense against viruses, including the induction of an "antiviral state".
IFNλ4 belongs to the interferon family of cytokines and is highly similar in amino 
acid sequence of  IFNλ3.  Their classification as interferons is due to their ability to 
induce an innate antiviral state, while their additional classification as cytokines is 
due to their (Sheppard et al., 2003)  chromosomal location as well as the fact that 
they are encoded by multiple exons, as opposed to a single exon, as most type-I IFNs 
are.
IFNλ4 was discovered in 2002 by Zymogenetics using a genomic screening process 
in which the entire human genome was scanned for putative genes, was named 
IL28B.  Once these genes were found, a second scan was performed to look 
specifically for cytokines. 
IFNλ4 genes are located near IFNλ3 on chromosome 19 in humans. The two isoforms
of are 96% homologous. Differences in function between the two forms remains 
unclear.
IFN-lambda has also been shown to play a role in the adaptive immune response, as 
its inclusion as an immune-adjuvant during small animal vaccination lead to 
augmented antigen-specific Interferon Gamma release as well as an increased 
cytotoxic potential in CD8+ T cells (Morrow et al., 2009).
Studies of IFNλ4 in non-human primate models of vaccination confirmed the small 
animal models, leading to an increase in Interferon Gamma production and CD8+ T 
cell activity in the form of cytotoxicity in an HIV vaccine study (Morrow et al., 
2010).
A single nucleotide polymorphism (SNP) near the IFNλ4 gene predicts response to 
hepatitis C treatment with interferon and ribavirin (Ge et al., 2009a). The SNP was 
identified in a genome-wide association study (GWAS – table 1) and is to date the 
best example of a successful GWAS hit that is clinically relevant (Maxmen, 2011).
Table 1: A list of SNPs studied by several group in the recent years
Genetics test
Genetic testing [GWAS] have recently identified host genetic variation to be critical 
for spontaneous clearance and treatment response in patients infected with hepatitis C
virus (HCV). Compared with all other baseline host and viral variables, different 
polymorphisms of the interferon lambda 4 gene, situated on chromosome 19, have 
been reported as the strongest predictors of HCV therapy response and spontaneous 
viral clearance. In this respect, the rs12979860 C and the rs8099917 T variants, 
located 3 and 8 kb upstream of the IFNλ4 gene, which have some level of linkage 
disequilibrium (R2: 0.50 in Caucasians), seem to be the two strongest genetic 
predictors. Beyond their identification, little is known about the mechanisms involved
between these genomic variants and viral clearance and it is still uncertain whether 
these polymorphisms play a causal role. It has been shown that unfavorable IFNλ4 
genetic variations are associated with higher pre-activated levels of ISGs, which 
could explain the more frequent chronicization and poor response to antiviral 
treatment in this patients. Data on the influence of the IFNλ4 gene polymorphisms on
the natural history of untreated chronic HCV infection are scarce. The correlation 
between IFNλ4 polymorphisms and progression of liver fibrosis is still controversial. 
Interestingly, Tillman et al., have reported that jaundice during acute hepatitis C is 
more common among patients with rs12979860 C/C genotype than non-C/C patients 
and that women with the C/T or T/T genotype who did not develop jaundice have a 
lower chance of spontaneous clearance of HCV infection.
It is unknown whether rs12979860 and rs8099917 exert direct biological effects or 
are in linkage disequilibrium with other functional polymorphisms. Several 
investigators have performed gene mapping failing to detect new single nucleotide 
polymorphisms (SNPs) with a stronger genetic effect or with a clear functional 
mechanism. Other studies, however, have demonstrated that the polymorphisms are 
associated with a change of methylation (loss or a gain of methylation), located 
within the 5' region upstream from the transcription start of the IFNλ4. Among them, 
rs4803221 is a C to G (C/G) polymorphisms resulting in a loss of methylation, 
located -500 bp upstream rs12979860 which has been associated with reduced 
clearance and response to treatment.
Recently the role of the IFNλ4 polymorphisms in influencing the spontaneous 
clearance of HCV, the response to interferon and the progression of liver fibrosis, was
also associated in patients with thalassemia major infected by genotype 1b.
Although hepatitis C is no longer a major threat in the European blood supply, these 
finding are relevant because HCV acquired through transfusion before the 
implementation of blood donor screening, remaining one of the most important 
problem among patients with thalassemia, given the reported high presence of HCV 
antibodies  in multi-transfused patients and a noteworthy prevalence of clinically 
significant fibrosis. 
Moreover, hepatocarcinoma is becoming frequent with the aging population of 
patients with thalassemia.
HCV replication cycle
General replication cycle for HCV infection is well known as well as the IFNλ4 entry
in one or more of those. General replication in figure 1 starts by the interaction 
between HCV-associated lipoprotein receptors: LDL-R and/or SR-BI and/or cell 
surface heparan sulphate proteoglycans (GAGs). HCV subsequently interacts with 
CD81, a “post-entry” receptor, which forms a complex with SB-BI. CD81 plays 
fundamental role in HCV infectivity as it triggers signaling cascades essential for 
virus entry and further downstream events (Brazzoli et al, 2008). The virus is then 
transferred to the tight junction proteins Claudin-1 (or Claudin-6 or Claudin-9, 
(Zheng et al., 2007)), and Occludin (Ploss et al., 2009) which provides “the final 
entry key” for HCV cellular uptake. E1 and E2 envelope glycoproteins mediate pH-
dependent fusion (Lavillette et al., 2007) with limiting membranes of early 
endosome, which trigger nucleocapsid release into the cell cytoplasm and permits the 
virus to escape the lipoprotein degradation pathway.
After virus cell entry, HCV-RNA replication takes place in membrane-associated 
replication complexes designated as membranous webs (Gosert et al., 2003). HCV 
replication complexes are subjected to intracellular transport, and their formation is 
closely linked to the dynamic organization of the endoplasmic reticulum, acting 
filaments and the microtubule network (Jones et al., 2007, Lai et al., 2008). However,
how the virus is trafficked from the virion attachment at the cell surface to the 
delivery of the viral genome to its replication site remains unclear.  Moreover 
microtubules play a key role in the early steps of the virus cycle, leading to the 
establishment of productive HCV infection (Budkowska et al., 2009).
 
Figure 1: Canonical HCV replication cycle. (Wong et al., 2014).
Innate antiviral response
First defense of hepatocyte against HCV is innate antiviral response.
The innate immune response, also known as the nonspecific immune system (Grasso 
et al., 2002), is an important subsystem of the overall immune system that comprises 
the cells and mechanisms that defend the host from infection by other organisms. The
cells of the innate system recognize and respond to pathogens in a generic way, but, 
unlike the adaptive immune system, it does not confer long-lasting or protective 
immunity to the host.
Recently has emerged a key role of IFNλ4 genotype in the induction of the innate 
antiviral immunity.
Rs12979860 (at the IFNλ4 locus) is strongly associated with HCV spontaneous 
clearance and treatment response, but the underlying mechanisms responsible in 
innate antiviral response remain unclear (Ge et al., 2009; Naggie et al., 2012; Thomas
et al., 2009; Urban et al., 2010).  IFNλ4 variants proteins correlated with unfavorable 
IFNλ4 genotype had less antiviral activity against HCV replicons and were capable to
determine a variation of ISG (IFN-stimulated genes) expression (Terczyńska-Dyla E. 
et al., 2014). Sheahan T. et al.(2014), confirms the association between IFNλ4 
polymorphism rs12979860 and the innate antiviral response though expression 
studies. While examining genotype-specific host responses, they observed that the 
numbers of significantly regulated genes increased stepwise from homozygous major 
to homozygous minor alleles HCV-infected cells. People with unfavorable genotype 
chronically infected with HCV typically have higher baseline levels of ISGs.
In order to understand poorly known mechanisms of spontaneous clearance in which 
IFNλ4 is involved, we used co-expression analysis method (WGCNA) from GEO 
dataset. To our knowledge, no weighted correlation network analysis is available in 
literature to describe interaction between IFNλ4  and HCV infection. 
Potential role of the IFNλ4 in the HCV response 
The molecular pathways that link the IFNλ4 genotype with antiviral effector systems 
of the innate and adaptive immune system are not known. However, substantial 
progress has been made in basic understanding of the induction of interferons through
toll-like receptor and RIG-I/MDA5 pathways, and of interferon-induced signaling 
pathways and antiviral effector systems.
HCV was able to interfere not only with IFN signaling through the Jak-STAT 
pathway (figure 2), but also with the translation of ISG mRNAs to proteins at the 
ribosomes. Elegant evidence for such a translational block has been obtained in 
Huh7.5 cells infected with HCV and treated with IFNα. In this system HCV infection
did not block the transcriptional induction of ISGs by IFNα. However, HCV infection
triggered phosphorylation and activation of the RNA-dependent protein kinase PKR, 
which inhibits eukaryotic translation initiation factor eIF2 alpha, and thereby cap-
dependent translation of cellular mRNAs, but not the IRES-dependent translation of 
HCV RNA (Horner et al., 2014). 
Figure 2: IFNλ4 role in HCV antiviral response.
Materials and Methods
Clinical study patients 
In the present study we retrospectively analyzed 511 patients with beta-thalassemia at
two Italian major centers in Cagliari and Turin transfused before 1990 and 122 
transfused after 1990 in which only four patients were infected with hepatitis C virus.
In totally we analyzed 418 patients that were infected. Two hundred and fifteen were 
anti-HCV negative and 168 anti-HCV positive. 
Of 418 patients infected we could extract DNA only of 368 patients, 364 before 1990 
and 4 after the implementation of blood donor screening in 1991. We have lost some 
patients due to several reasons like denaturation of DNA of old patients that we had 
available.
Figure 3: HCV status in Beta-Thalassemia Mayor in the cohort. 
Neg-neg = Anti-hcv neg - RNA neg, pos-neg = Anti-hcv pos - RNA neg, pos-pos = Anti-hcv pos
- RNA pos
Viral genotype was known in 215 patients. One hundred thirty-three subject with 
chronic infection had been infected by severe genotypes (1 or 4) and 83 by side 
genotypes (2,3 or 5).
Clinical data
The 368 anti-HCV positive patients were genotyped at the polymorphic sites on 
chromosome 19. The relationship between IFNλ4 variants, liver necrotic-
inflammation, and fibrosis was evaluated. Although the bilirubin values during the 
acute phase of hepatitis C were not available, four values per year until 2010 for the 
last 20 years per patient (or until the antiviral treatment) were recorded by mean of 
Webthal, a Web-Based Multicentric DataBase, as well as ALT and serum ferritin 
values measured at the same time. The use of Webthal for the clinical follow-up of 
the patients and for scientific purposes was approved by the Ethics Committees of the
two hospitals. All patients registered in WebThal signed informed consent to the use 
of their clinical data for research studies and objectives. Moreover, each patient, and 
their parents if minor, signed a written consent for DNA testing.
Among 368 anti-HCV positive patients 149 (40,5%) had spontaneously cleared  the 
virus (HCV+/RNA-) and 219 (59.5%) were chronically infected (HCV+/RNA+), at 
least at a biannual determination by real time PCR. 
Table 2: Records description
244 patients came from Sardinia, Microcitemico of Cagliari divided in pediatric 
patients (164) and adult patients (80), while 116 patients came from pediatric center 
of Turin.
Of our cohort of beta-thalassemic major, we have evaluated the frequency of the 
rs12979860 genotypes (figure 4).
Recessive genotype (TT) have a frequency in whole cohort equal to 12,5%, 
heterozygous (CT) has 47%, and dominant homozygous (CC) has 40,5%.
Even without statistical tests it is straightforward the difference in the TT genotype 
behavor, as those that maintain virus persistence have 18% of frequencies  and vice-
versa the population in clearance has only 3% of this genotype. Also CC change in 
frequency when observing cleared patients (52%) or persisted patients (31%). 
Figure 4: Rs12979860 frequency
IFNλ4 genotype
Three SNPs, rs12979860, rs8099917, and rs4803221 were genotyped. DNA was 
extracted from venous peripheral blood with standard methods while SNPs were 
directly genotyped using ABI TaqMan assay (Applied Biosystem Warrington, UK). 
SNP details as well as genotype frequency measures are reported on figure 4 for 
clearance virus.
Ninety four HCV-RNA positive patients had undergone liver biopsy and none of 
them had received antiviral therapy before. Mean age at the time of liver biopsy was 
20+/-5 years.
Fifty patients had been treated with Interferon in the '90s of whom 20 presented 
sustained virological response (SVR) and 30 presented non sustained virological 
response (NSVR).
Since 2010, most patients with chronic persistent HCV infection received Peg-
interferon and ribavirin, but, having only 27 of them completed the treatment since at 
least 6 month, the correlation between IFNλ4 polymorphisms and the response to this
kind of treatment could not be evaluated due to the low number.
Haplotypes
We constructed haplotype from the two best SNPs of IFNλ4 in patients chronically 
infected and in patients who cleared virus.
SNPs data were phased using PHASE software (Stephens M. et al., 2003) and kept 
when phasing probability was higher than 0.9.
Differences between groups were tested using genotype test as implemented in p-
Link software and Mann-Whitney U-test upon data characteristics.
Furthermore, to check whether SNPs or haplotypes frequencies were associated with 
spontaneous viral response while controlling for confounders, a binary logistic 
regression model was developed. Goodness of fit of the model was assessed through 
Hosmer & Lemoshow test while Nagelkerke R2 was used to measure how useful 
explanatory variables were in predicting the outcome. 
Statistical methods
The Mann-Whitney, U-test or Student's test were used to compare continuous 
variables, and the chi-square were used to compare categorical variables. Univariate 
logistic regression was used to assess odd ratios of factors associated with sustained 
virological response. Multivariate analysis included all parameters from univariate 
analysis with a p-value <0.2. Receiver operator curves (ROC) were constructed to 
evaluate the areas under curve regarding spontaneous viral clearance associated with 
the SNPs and Haplotype.
All genetic analysis were performed using the PLINK software, version 1.07 (Purcell 
S. et al. 2007) while the SPSS statistical software package, version 18 (SPSS, IBM, 
Somers, NY, USA), was used for subsequent analysis, using a critical alpha of 0.05. 
Patients characteristics were described as relative frequencies or median with 5th and 
95th percentile values.
Linkage disequilibrium between SNPs was assessed by Haploview version 4.2, which
provided D' and r2 values.
Statistical analysis
1)  χ2 and fisher and LogReg for SNPs/Haplotype/confounders
2) ROC for prediction ability
3) Decisional Tree description
4) Statistical package and significance
SNPs and Haplotypes frequencies were compared between groups using Chi-square 
and fisher exact test when appropriate, and also we performed Logistic Regression to 
account for confounders.
ROC curve analysis was performed to compare single SNPs and Haplotypes 
predictive ability, evaluating the area under the curve.
All p-value presented are two tailed and a value of p>0.05 was considered 
statistically significant, and PLINK v.1.07, PHASE v.2.1 was used to generate 
haplotype data.
Mann-Whitney test was conducted to compare medians. The significance of 
associations between genotype/alleles variants and susceptibility to infection or 
spontaneous clearance were assessed using Chi-square and Fisher's tests with an 
estimation of the risk by computing OR (odd ratio). 
A p-value <0.05 was considered statistically significant. All tests were two-sided.
Haplotype frequencies and pairwise differences bet groups analyzes were performed 
using PHASE.
GEO dataset
We have downloaded a public expression dataset in order to develop co-expression 
network study. Expression data were already normalized  to a housekeeping gene, 
beta actin, and donor and time-matched mock-infected samples using the comparative
Ct method developed by Schmittgen and Livak (2008).
That dataset is downloadable at NCBI GEO DATASET, can be found at 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE54648.
Dataset GSE54648 samples (Sheharan et al , 2014) derived from culture of PHHs 
(primary human hepatocyte), offering an attractive alternative to human 
environmental. Like native hepatocytes. PHHs are polarized, largely terminally 
differentiated, and can robustly upregulate the innate immune response upon 
infection. The hepatocytes were infected with HCV genotype 2a. Association 
between IFNλ4 and effective antiviral response was determined by comparing IFNλ4 
genotype with high and low infection frequencies in HCV infected cells (named high,
medium, low “donors”).
Sheahran's study revealed that hepatocytes from infection frequencies with clinically 
less favorable IFNλ4 genotype (rs12979860, minor allele T/T) were more permissive 
for HCV infection (high or medium donors) compared to the cells with favorable 
alleles (rs12979860, major allele C/C), that were low donors (table 1).
We selected dataset from 20 cDNA libraries amplified from whole-genome 
microarray, hybridized to Illumina Whole-Genome Expression BeadChips (Illumina, 
HumanHT-12 V4 0 R2), from a total of 188 amplified cDNA libraries generated from
LCM (Laser Capture Microdissection) samples of mock, HCV-infected, and adjacent 
hepatocytes.
The cDNA amplified selected for our aim were HCV infected cells. Moreover, we 
selected cells captured on 1dpi (day post infection) and 3dpi, excluding cells on 7 dpi,
because during 7dpi occurred a reduction of infection frequencies for all rs12979860 
genotype.
Our restricted selection from original dataset  was composed by 12 cDNA libraries 
from cells with TT genotype (8 high donors and 4 medium donors) and 8 cDNA 
libraries from cells with CC genotype (all low donors) in order to discover the 
greatest difference between favorable and unfavorable genotype(Table 3)
Table3: (A) Description of the major and minor alleles for IFNλ4. IFNλ4 and SLC45A2
genotype data for all cell type and their relation to infection frequency. Infection frequency
classification is based on the infection frequency for each cell at 1 day (dpi) and 3 dpi.
SLC45A2 can predict European or African ethnicity In red are highlighted cell chosen for our
analysis. (Sheahan T. et al., 2014).
WGCNA – R package
WGCNA begins with the understanding that information captured by microarray 
experiments is far richer than a list of differentially expressed genes. Rather, 
microarray data are more completely represented by considering the relationships 
between measured transcripts, which can be assessed by pair-wise correlations 
between gene expression profiles. In most microarray  analyses, however, these 
relationships go essentially unexplored. WGCNA starts from the level of thousands 
of genes, identifies clinically interesting gene modules and finally uses intramodular 
connectivity, gene significance (based on the correlation of a gene expression profile 
with a sample trait) to identify key genes in the disease pathways for further 
validation (Langfelder P. et al., 2008). WGCNA alleviates the multiple testing 
problem inherent in microarray data analysis. Instead of relating thousands of genes 
to a microarray sample trait, it focuses on the relationship between a few modules and
the sample trait. We excluded outliers through observing cluster graph, all samples 
that cross red abline, will be deleted to avoid artifacts. Toward this end, it calculates 
the eigengene significance (correlation between sample trait and eigengene) and the 
corresponding p-value for each module.
The module definition does not make use of a priori defined gene sets. Instead, 
modules are constructed from the expression data by using hierarchical clustering. 
Although it is advisable to relate the resulting modules to gene ontology information 
to assess their biological plausibility, it is not required. Because the modules may 
correspond to biological pathways, focusing the analysis on intramodular hub genes 
amounts to a biologically motivated data reduction scheme. Because the expression 
profiles of intramodular hub genes are highly correlated, typically dozen of candidate 
biomarkers result. Although these candidates are statistically equivalent they may 
differ in terms of biological plausibility or clinical utility. Gene ontology information 
can be useful for further prioritizing intramodular hub genes.
Figure 5: WGCNA standard proof-of-concept analysis
Co-expression network is defined as undirected, weighted gene networks. The nodes 
of such network correspond to gene expression profiles and edges between genes are 
determined by the pairwise correlations between gene expression. Finally, Cytoscape 
version 3.2 and its plug-in Cluego software were used to visualize networks.
Weighted Gene Co-expression Network Analysis
WGCNA is based on topological overlap measurements derived from pairwise 
correlation-based adjacency values to estimate the neighborhood similarity among 
genes, followed by hierarchical clustering to identify gene (Figure 5) co-expression 
modules. Instead of focusing on individual genes WGCNA is highly effective for 
characterizing the feature of co-expression gene modules each of which is 
represented by a color classifier (modules). Here the correlation power is raised by a 
power of 10 to satisfy scale-free criteria. The minimum module size was set to 20 
genes and the height for merging modules was set to 0.25. which required at least 
25% dissimilarity among modules in expression, and network type was “signed”.
We identified several modules, each summarized by its eigengene (ME, defined as 
the first principal component of the standardized expression values). The significant 
of module eigengen-phenotype association (rs129798860 genotype, Donors, days or 
SLC45A2) was evaluated by linear regression model using WGCNA function.
Association less than 0,05 (Bonferroni Correction) was considered as significant. The
top kME connection or the top gene was selected in order to facilitate visualization. 
Functional enrichment analysis
Functional enrichment analysis was assessed using gene ontology categories.   The 
background was set to the total list of genes expressed in this data set.
Gene are selected on the basis of MM (module membership) value color >0.6 or <-
0.6, always if cross the p-value threshold, and then selected the best genes with 
highest absolute MM values. Subsequently all gene selected were used as input of a 
functional enrichment analysis in KEGG using Cluego.
Result
Polymorphisms significance
Table 4: Genotype frequencies of IFNλ4 polymorphisms in 368 subjects with beta thalassemia
and anti-HCV antibodies. The frequencies were calculated in the whole group and separately,
in HCVRNA positive and HCVRNA negative patients. AUC= area under the curve.
As shown in table 4, rs12979860 and rs4803221 were the polymorphisms more 
associated with viral clearance and persistence (p=3.8E-7 and p=4.0E-7 respectively).
The positive predictive power (PPP) of rs 12979860 was stronger for viral persistence
than for spontaneous clearance (PPP=91%) and in such respect it corresponded to a 
recessive model for the T allele (p=3.8E-4 for TT versus CT genotype while p=0.08 
for CT versus CC genotype). On the other hand, a dominant model for the C allele of 
rs12979860 was not alike predictive of viral clearance (PPP=0.52) (figure 6).
49  patients  had  been  treated  with  Interferon  in  the  ‘90s,  of  whom 19  presented
sustained  virological  response  (SVR)  and  30  presented  non  sustained  virological
response (NSVR). Since 2010, most patients with chronic  persistent HCV infection
received Peg-interferon and ribavirin,  but,  having only 27 of  them completed the
treatment since at least 6 months, the correlation between IFNλ4 polymorphisms and
response to this kind of treatment could not be evaluated due to the low number. 
Figure 6: Positive predictive power of rs12979860 polymorphisms in respect of viral
persistence and of spontaneous clearance. The positive predictive power (PPP) of rs12979860
was stronger for viral persistence than for spontaneous clearance and a recessive model for
the T allele was the most predictive of viral persistence.
 Table 5: Genotype frequencies of IFNλ4 polymorphisms in 368 subjects with beta thalassemia
infected with Hepatitis C virus and  treatment with interferon-alpha. The frequencies were
calculated in the whole group and separately, in responder and non responder
Rs12979860 and rs4803221 were also associated with SVR and NSVR (p=0.028 and 
p=0.063 respectively). Among 49 patients treated with interferon 19 achieved a SVR. 
None of them carried the T/T genotype in the rs12979860 while 12 were C/C. Vice-
versa, among 30 patients with persistent HCV viremia (non responder) 7 patients 
carrying recessive genotype (T/T) versus no one in SVR (responder), and with a 
frequency of 50% in dominant genotype with 13 out of 19 patients who achieved a 
SVR (table 5)
Due to low records number unfortunately for this test we don't have enough statistical
power.
Clinical data Associations
Binary logistic regression analysis, including rs12979860, rs4803221, gender and 
UGT1A1, showed that not categorized rs4803221 as well as genotype TT of 
rs12979860 were associated with viral persistence (OR= 2.36 p=0.007 and OR=6.04 
p=0.02 respectively). Rs8099917 was not included in the model for its almost 
complete linkage disequilibrium with rs4803221.
Table 6: Clinical evidence – In red is reported the p-value for each test
As expected, patients with chronic persistent HCV infection had mean ALT values of 
the last 22 years significantly higher than patients who had cleared the virus (47,8+/- 
30,6 vs 91.3+/-57,3 ,  p=6.2E-19). 
However, among HCV-RNA positive patients, mean ALT values were not related to 
the rs12979860 and rs4803221 polymorphisms (p=0.76 as for rs12979860 and 
p=0.66 as for rs4803221). On the contrary, mean ALT were significantly related to 
mean serum ferritin values both in patients with chronic infection and in those who 
cleared the virus (p=1.25E-09 and 2.58E-03, respectively) and serum ferritin was not 
statistically different in the two groups of patients (1990 +/- 1290 ng/mL vs 2020 +/- 
1440 mg/mL, p=0,984). Mean total bilirubin values were not statistically different 
between HCV-RNA positive and negative patients (1,7 vs 1,8 ,p=0,435), and among 
HCV-RNA positive, with respect to the rs12979860 and rs4803221 polymorphisms 
(p=0.14 and 0.09, respectively).
By the Desmet score, 16 patients (17%), had no fibrosis, 35 (37.2%) had mild fibrosis
(F1), 24 (25.5%), moderate fibrosis (F2), 17 (18.1%) sever fibrosis (F3) and 2 (F4) 
had cirrhosis. 
Rs12979860 C/C genotype was present in 24 patients with F0-F2 and 9 patients with 
F3-F4 C/T in 46 patients with F0-F2 and 8 patients with F3-F4 and T/T in 5 patients 
with F3-F4  and C/T in 2 patients with F3-F4 and C/C (p=0.26). As for rs4803221, 
G/G genotype was present in 37 patients with F0-F2 and 11 patients with F3-F4, C/G 
in 34 patients with F0-F2 and 8 patients with F3-F4 and T/T in 4 patients with F3/F4 
and no patients with F0-F2 (p=0.75). However, the present study is underpowered to 
observe clinically relevant differences in proportion, indeed we only have 20% power
to observe a 10% difference between group F0-F2 and F3-F4 with the present sample 
size (table 7).
Table 7: Statistical Test to evaluate significance between Desmet score and IFNλ4 variants.
Haplotype analysis
Four SNPs were genotyped: rs7248668, rs4803221, rs12979860, rs8099917  (Ge et 
al., 2009b), after GWAS study of all chromosome 19 (figure 9) imputed with 1000 
genomes database using hg19 (GRCh37). We used as cases HCV infected and cleared
to the infection and as controls HCV infected and in persistence.
GWAs  confirmed the two just known SNPs rs12979860, rs8099917 and two less 
described SNPs (rs7248668, rs4803221,) (Smith et al., 2011).
These SNPs are in complete Linkage Disequilibrium (figure 8) in couple in the other 
hand rs12979860 is in complete LD with  rs7248668 and  rs8099917 is in complete 
LD with rs4803221. The final haplotype was built with only  rs12979860 and  
rs4803221 that are the best predictors for each couple of LD.
The polymorphism rs8099917, was observed to have a high linkage disequilibrium 
with rs4803221 (R2=0.9), while rs12979860 showed a low linkage disequilibrium 
with rs8099917 or rs4803221 (R2=0.43 and 0.47 respectively).
Figure 7: LD block of all IFNλ4 region. 
GWAS result confirmed rs4803221 responds better than the current best rs8099917 
also in our beta-thalassemic population replaying the result of Smith.
 Figure 8: LD block where the numbers above the graph correspond respectively to: 1:
rs7248669,  2: rs8099917, 3: rs4803221, 4: rs12979860
Moreover, in our population, while rs8099917 has an almost complete LD with 
rs4803221 the methylation associated polymorphism rs4803221 has independent 
effect with respect to rs12979860. This finding led us to develop an algorithm that, 
considering rs4803221, significantly may improve the viral clearance prediction in 
patients presenting the T allele at rs12979860. Recently, the same rs4803221 was 
found to predict failure to respond to antiviral therapy better than rs8099917 and 
rs12979860 in 199 treated patients infected by C genotype 1.
Haplotype Study, decisional Tree, and ROC curve
Predictive ability of haplotypes formed by rs4803221 and rs129798860 (table 10), as 
well as haplotype formed by all three SNPs, compared to predictive ability of the best
predictor single SNP (rs12979860) using ROC curve analysis(figure 9), showed that 
the haplotype including rs4803221 and rs12979860 was only sightly less predictive 
than haplotype including all the three SNPs (AUC=0.656 and AUC=657 
respectively). On the other hand the haplotype including rs4803221 and rs12979860 
outperformed rs12979860 in predicting viral clearance (AUC=0.635).
Table 10 :IFNλ4 haplotype study for two best predictors SNP in spontaneous clearance
Figure 9: Predictive ability of viral clearance of single SNPs and haplotypes using ROC
curve analysis.
In the same way decisional tree (figure 11) described what happened in the haplotype 
with rs12979860 T (minor allele) genotype and rs4803221 C genotype (minor allele).
In figure 11 is shown the increase of prediction, as decisional tree, in the persistence 
infection of hepatitis C virus, this could lead a better diagnosis in clinical 
management.
Figure 11: Decisional Tree to see the impact of the rs4803221 polymorphism analysis on viral
clearance prediction. 
Co-expression enrichment analysis
Using co-expression analysis in public expression data previously described, we have
weighed array data for “donors” and for rs12979860. On this study we expected to 
find a correlation between rs12979860 unfavorable genotype TT and favorable 
genotype CC in HCV infected cell.
Following standard WGCNA workflow we obtained, after clusterization and module 
generation, the enrichment table depending on module colors, for the 20 samples 
selected.
Enrichment analysis revealed as the most significant modules “purple” and “white” 
(table 8). “Purple” module belongs to pathways related to retinoic acid receptor. It’s 
known that RIG-I, is a retinoic acid-inducible gene 1 and it belongs to one of the 
main biological process involved in PRR (pattern recognition receptor). At  the 
“white” modules belong pathways related to translation and transcription, protein 
localization and protein transport, mechanisms already known to be activated in HCV
infected cell.
Table 8. Color Pathways depend on module colors. All are close related to ribosome process
(translation and transcription). Enrichment analysis of the CC vs TT rs12979860 WGCNA
result (had also pathways relate to  retinoic acid where the most known for HCV interaction is
RIG-I).
At a next step, we kept first 9830 best genes of first analyses (selected for p-value < 
0.05), in order to resolve computational problem in “eigengene” analysis due to work 
with more than 47324 genes: we have made a large selection of genes inside the best 
module found. Obviously new selected genes test compared with all genes test got 
similar results, but since we have to change “soft-thresholding power”, modules color
were different from first co-expression analysis (module color depends number of 
genes), we had as best modules “yellow” and “black” (table 9). 
Table 9: WGCNA analysis performed with 9830 best genes found in CC vs TT analysis made
with 47324 genes.
Relationship between module color and rs12979860 showed an high correlation 
between “black” module and trait, vice-versa even if we had significant p-value in 
“yellow” module (table 9) doesn't exist a direct correlation with rs12979860, as 
possible as to see in the “MEyellow” row (figure 12).
Eigengene cluster graphs highlighted the correlation between genes and modules for 
CC vs TT and weighted for donors (figure 13 (a)), or for the rs12979860 genotype 
(figure 13 (b)). Also the dendrogram indicates that “black” module is highly related 
in weights chosen, indeed the “black” module had stronger correlation than other 
modules.
Figure 12: Relationship between module color and traits. Dark red represent positive
correlation and dark green represent negative correlation. Black module is the most
correlated.
Both dendrograms had the same clusterization, validating the thesis for which IFNλ4 
variants and HCV infection are associated. Even if the highest enriched terms for 
“yellow” module was 2.6e-8 whereas the highest enriched terms for “black” module 
was 1.2e-5, “yellow” module is not part of the same meta-module. On the other hand,
even if the “yellow” module had better p-values significance (table 9), it’s not 
directly associated to rs12979860.
Then, with genes inside “black” module we constructed genes networks using 
Cytoscape in order to detect hubs (genes with driver positions and strong connection 
each others) related to SNP genotype (figure 14(a)). 
Figure 13: Eigengene dendrogram. (a) weighed for “donors”, (b) weighed for rs12979860
genotype. Red highlighted represent the closest meta-module for each dendrogram. “Black”
module is confirmed to be the most related.
Genes with the higher number of correlation were LOC389404 (RPL9P18), 
LOC727865 (RPL9P32) and LOC651436 (similar RPL9) that we can consider as hub
genes of black module. Furthermore this three hub were undirectly linked by 
LOC441763 with RNA28S5 (LOC100008589) that was the best rank gene in module
(the gene with the best p-value associated to rs12979860), shown in table 10.
 
Table 10: All 72 gene in  black module. Green highlighted are genes present in Cytoscape
network. And in red are highlighted the best genes. LOC389404 is RPL9P18 the hub genes in
network and LOC100008589 is RNA28S5 the best rank in gene associated to rs12979860.
Enrichment analysis made with Cluego showed in figure 14(b) had two main 
networks that links in same genes. We just expected this kind of result, due to 
intrinsic mechanism in HCV infection. This result suggests that innate antiviral 
response may be hub regulated by pseudogenes (Yan-ZI Wen et al. 2012) indeed 
unfavorable genotype rs12979860 TT had an overexpression of RPL9P18, RPL9P32, 
LOC651436 (RPL9 like)  and RNA28S5.
The network built in Cluego reveal pathways related to mRNA catabolic process, 
cytosolic ribosome, translational termination, cytosolic small ribosomal subunit, 
cotranslational protein targeting to membrane, SRP-dependent cotranslational protein
targeting to membrane,translational elongation.
(a)
(b)
Figure 14: (a) Network displayed genes with higher correlation with rs12979860. RPL9 and
RPL9 pseudogenes are the higher correlated, however other ribosome subunits have a central
role. (b) Enrichment analysis made with Cluego shows closest pertinent pathways of the main
ribosome subunits genes (RPS20, RPS25, RPS29, RPL9).
Discussion 
Clinical evidence
The aim of first part of our study was to examine the prevalence and clinical 
significance of SNPs within the IFNλ3/IFNλ4 alleles in a population of HCV-infected
patients in Sardinia. We also evaluated the ability to predict response to anti-HCV 
treatments in this population. We found that rs12979860 and rs4803221 were the 
most informative markers of treatment response and spontaneous clearance in 
Sardinia.
Finally we show that combined polymorphisms may show increased predictive value 
in term of spontaneous clearance, with a significant improvements in the associations.
Clinical Data Association
We have demonstrated that in thalassemia patients the rs12979860 as the rs4803221 
polymorphisms are not associated with necrotic-inflammation, differently from that 
reported by Agundez et al. and Thompson et al. who have found in general population
that rs12979860 C/C genotype is associated with higher serum ALT than the 
remaining genotype and by Abe et al. who found that ALT levels were lower in 
carrier of the rs8099917 T/T genotype. This difference could be due to the 
confounding effect of liver iron, which as a primary role in inducing liver damage in 
subject with thalassemia, as demonstrated by the highly significant relation between 
mean ALT and mean serum ferritin values in our patients. Tillman reported that the 
jaundice during acute hepatitis C is more common among patients with rs12979860 
C/C genotype than with other variants and that in non-C/C patients, jaundice is 
associated with a higher likelihood of spontaneous clearance compared with those 
without jaundice. Although we could not confirm or deny these findings, no 
correlation was found between UGT1A1 polymorphisms and persistence of the virus.
In addition, the total bilirubin long follow-up allowed us to demonstrate for the first 
time that, at least in patients with beta-thalassemia, there is no correlation between 
rs12979860 polymorphisms and bilirubin values, which are confirmed to be strictly 
dependent on the UGT1A1 polymorphisms.
The relation between IFNλ4 polymorphisms and the stage of fibrosis is controversial.
Di Marco et al. (2012) reported that the carrier state of the minor alleles at 
rs12979860 and rs8099917 sites were associated with more severe liver fibrosis in a 
group of 131 patients with thalassemia major and chronic HCV infection. In general 
population, several authors found higher fibrosis among carriers of the rs8099917 T/T
genotype. Nevertheless Thompson et al. reported that the rs12979860 polymorphism 
was not associated with advanced hepatitis fibrosis in patients with virus C chronic 
hepatitis, and Agundez et al. did not find any relation among the IFNλ4 
polymorphisms and fibrosis stage directly shown by the liver biopsy. These finding 
are in agreement with our results. Even though the number of patients undergone 
liver biopsy in out study is smaller than those examined by Di Marco et al. the lack of
association between necrotic-inflammation and IFNλ4 polymorphisms and the 
previously demonstrated significant correlation between rate of fibrosis progression 
and hepatitis iron concentration in HCV-positive patients with thalassemia could 
explain and support these observations.
Frequency analysis
This study confirm that, in thalassemia patients as in general population, the SNPs on
chromosome 19q13 closely associates with innate natural course and treatment 
response of chronic hepatitis C. As on a recent paper, indeed, also in our population, 
C/C variant of polymorphism rs12979860 was related to response to interferon 
treatment and, above all, to spontaneous clearance of the virus. However, it seems 
noteworthy to underline that, as for rs12979860, the positive predictive power was 
stronger for viral persistence than spontaneous clearance and in such respect the TT 
allele was more predictive than CC.
Further studies are needed to demonstrate that the haplotype tagged by SNP 
rs12979860 and rs4803221 is the major causative.
WGCNA analysis
In second part of our study, based on differentially expressed genes, we employed 
WGCNA analysis to construct co-expression network analysis for 47324 genes  in 
HCV infection in PHH.
Our study demonstrated that WGCNA is useful for exploring transcriptional changes 
and identifying difference between HCV-infected cell frequency associated to IFNλ4 
genotype rs12979860. Our results may help to explain biological process occurred in 
early HCV infection and in particular the deeper role of unfavorable rs12979860 
genotype. We identified 72 genes (table 10) in “black” modules which had as mainly 
hub (RPL9P18).
We observed an overexpression of ribosomal genes when rs12979860 has TT 
genotype. This could means that TT genotype encourage overexpression of specific 
ribosomal pseudogenes (RPL9P18, RPL9P32) probably decreasing innate antiviral 
response either at the level of ISG regulation or at the level of ISRE mechanism 
regulation (Prokunina-Olsson et al., 2013).
RPL9P18, has a known transcript (ENST00000439124) of 535 bp, located on 
Chromosome 6: 63,615,827-63,616,361 reverse strand, to date is classified as 
processed pseudogene.
RPL9P32  has a known transcript (ENST00000495117) of 578 bp, located on 
Chromosome 18: 58,631,259-58,632,120 forward strand, to date is classified as 
processed pseudogene.
This evidence could likely suggests the  function of pseudogene transcripts as decoys 
of miRNAs in which pseudogene competes for miRNA with normal transcript gene. 
(Muro et al., 2011), on the other hand, an increase in the pseudogene transcription 
implies that less miRNA will target the parental gene. Therefore the pseudogenes 
indirectly regulate the corresponding parental gene by competing for binding to the 
miRNA.
Our analysis establish a prior event in which HCV response is highly associated with 
RPL9P18 (as hub) and RNA28S5 (as best p-value single gene) and it is conditioned 
by IFNλ4 genotype (figure 14(a)). 
From those relevant results appear straightforward two aspects: (1) IFNλ4 
unfavorable genotype is correlated to the ribosomal function; (2) specific 
pseudogenes could be an active role in innate antiviral response gene regulation.
Nevertheless we don't know if pseudogenes overexpression change function, gain 
function, lose function or none of this, interacting in other way, but we can suppose 
an active role in regulation of ribosomal genes.
Conclusion
In conclusion, also in thalassemia the SNPs on chromosome 19q13 closely associates 
with spontaneous clearance and drug treated, induced HCV clearance. The haplotype 
tagged by SNP rs12979860 and rs4803221 significantly could improve the viral 
clearance prediction in infected patients. Neither necrotic-inflammation, bilirubin 
values in the chronic phase of the hepatitis C or fibrosis stage are related to IFNλ4 
polymorphisms.
The network was constructed using WGCNA, R package, in two different steps based
on screening best modules after a primary detection, and further analyzed by 
Cytoscape network. Network showed genes with high module membership value and 
neighborhood connectivity involved in HCV infection which have different 
interaction depending on rs12979860 genotype.
We found the most likely hub RPL9P18 could be valuable as candidate genes in 
further functional analysis.
However, HCV host cell array co-expressed for rs12979860 genotype confirms 
several mechanisms of innate immune regulation and evasion could provide a 
molecular basis for viral persistence.
Further analysis could be necessary in order to validate this result, in particular  
knockdown study essentially to see if that ribosome subunits change expression or 
change viral response in significant way.
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